Skip to main content
An official website of the United States government

Durvalumab

Placeholder slot
 (dur-VAL-yoo-mab)

This page contains brief information about durvalumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Imfinzi
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Durvalumab is approved to treat adults with:

Durvalumab is also being studied in the treatment of other types of cancer.

More About Durvalumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Durvalumab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

More Immunotherapy Options Approved for Treating Endometrial Cancer

Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer

Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects

Targeted Therapy to Treat Cancer

Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer

Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Clinical Trials Accepting Patients

Find Clinical Trials for Durvalumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email